Navigation Links
Neurobiological Technologies Reports Third Quarter Financial Results
Date:5/12/2008

of its auction rate securities, which are now classified as long-term investments, by approximately $1.8 million based on uncertainties in the credit markets.

"We are very pleased to have recently and successfully passed our fifth Data Safety Monitoring Board assessment of the Viprinex(TM) phase 3 clinical trials that are currently underway," stated Paul E. Freiman, president and chief executive officer of NTI. "In addition, during the quarter we signed an agreement with the Buck Institute for Age Research that provides us development rights to an exciting compound in early development for the potential treatment of Alzheimer's disease. We also amended our agreement with Merz Pharmaceuticals and Children's Medical Center Corporation, effectively lengthening the term for which they are committed to pay us royalties on the sales of memantine, although at a lower rate than we received previously."

"Looking forward, we are excited about the prospects for our key asset, Viprinex, which has the potential to be the first new drug approved for the treatment of stroke in over ten years," continued Mr. Freiman. "Our main focus as a company is the development of this drug candidate, and the development of this asset is where substantially all of our operating funds are being spent. We believe Viprinex has the potential to double the treatment window over the current approved drug, while at the same time reducing the major side effect of symptomatic intracranial hemorrhage."

Conference Call Information

NTI will webcast its quarterly financial results and host a conference call on Tuesday, May 13, 2008 at 10:30 a.m. (ET), 7:30 a.m. (PT). Dial-in number (877) 591-4953 (U.S. and Canada) and 719-325-4851 (International). The live webcast can be accessed by going to http://investor.shareholder.com/ntii/events.cfm . A playback of the conference call will be available from 1:30 p.m
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Sets Date for Third Quarter Financial Results
2. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
3. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
4. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies Sets Date for Research and Development Day
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies Sets Date for Second Quarter Financial Results
10. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... According to a new market research ... & Non-Portable), Component (Accelerometer, Proximity Probe, & Others), ... Mining, & Others), & Geography - Global Forecast ... reach $1,453.76 Million by 2020, at a CAGR ... and 92 figures spread through 205 pages and ...
(Date:4/29/2015)... GUELPH, ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... twelve-month periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , ... 1,191 , 1,493 , 3,377 , ...
(Date:4/29/2015)... EAST RUTHERFORD, N.J. , April 29, 2015 ... 2015 financial results will be released on Friday, May 1, ... The Company will host a conference ... Conference Call When: , Friday, ... Dial-in: , 1-888-468-2440 for U.S.1-719-325-2454 for International ...
(Date:4/29/2015)... (PRWEB) April 29, 2015 The leading ... announce that its regenerative stem cell therapy has processed ... 2002, seeking to discover a successful treatment for horses ... In 2003 VetStem signed a worldwide exclusive license for ... and the first horse was treated in January 2004. ...
Breaking Biology Technology:Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
... applications for the real world, has formalized ... Inc. One of the many businesses that ... Tier 1 automotive supplier focusing on technology-rich ... and Lumidigm will bring patented biometric functionality ...
... N.J., Aug. 5 Ortho Biotech is announcing,that it is voluntarily ... cracks in the necks of a,small number of vials upon post-manufacturing ... Approximately 44,292 vials of lot,P114942A in the following packaging configurations were ... NDC ...
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial ... 2008., Replidyne reported a net loss of $18.7 million ... per basic and diluted common share of $0.69,per share, compared ... share or $1.65 per common share on a fully diluted ...
Cached Biology Technology: Lumidigm Signs Strategic Agreement with Methode Electronics : Automotive Supplier Invests in Biometric Component Development 2Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A 2Replidyne Announces Second Quarter 2008 Results From Operations 2Replidyne Announces Second Quarter 2008 Results From Operations 3Replidyne Announces Second Quarter 2008 Results From Operations 4Replidyne Announces Second Quarter 2008 Results From Operations 5Replidyne Announces Second Quarter 2008 Results From Operations 6Replidyne Announces Second Quarter 2008 Results From Operations 7
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... American Pregnancy Association, six million women a year deal with ... hope to women who want to conceive ― in the ... shelves right now. Prof. Adrian Shulman of Tel Aviv ... has found a statistical connection between the over-the-counter vitamin supplement ...
... at the Living Planet Symposium have been hearing about ... almost three months, the satellite is in excellent health ... presented at the symposium. Prof. Duncan Wingham, Lead ... in very good shape exceeding in-orbit specifications, the ...
... study of the occurrence of fishes in the ocean,s deepest ... species of fishes are more numerous at such depths than ... published in the July/August issue of BioScience , observed ... meters around a baited video lander in the Japan Trench. ...
Cached Biology News:Increasing fertility threefold 2CryoSat-2 exceeding expectations 2Study suggests more fish than thought may thrive in the ocean's depths 2
...
Use as the souce of CETP enzyme for screening CETP inhibitors. Use in conjunction with the CETP activity assay kit (K601-100)....
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Biology Products: